论文部分内容阅读
目的分析肿瘤标志物N S E和CYFRA21-1联合检测在肺癌诊断中的价值。方法将我院2014年1月~2015年5月收治的132例肺部疾病患者依据疾病类型分为观察组(70例)和对照组(62例),观察组为肺癌确诊患者,对照组为结核、肺炎病人。对两组患者进行NSE和CYFRA21-1联合检测。结果观察组及对照组NSE单独检测的阳性率为37.14%及35.48%;CYFRA21-1单独检测的阳性率分别为50.00%及48.39%;两组患者单独检测的阳性率相比无显著差异(P>0.05)。观察组及对照组联合检测的阳性率分别为84.29%及50.00%,组间比较差异显著(P<0.05)。结论联合检测血清肿瘤标志物NSE及CYFRA21-1可在极大程度上提高肺癌的诊断阳性率,可对后续治疗进行指导。
Objective To analyze the value of combined detection of tumor markers N S E and CYFRA21-1 in the diagnosis of lung cancer. Methods A total of 132 cases of pulmonary diseases admitted from January 2014 to May 2015 in our hospital were divided into observation group (70 cases) and control group (62 cases) according to the type of disease. The observation group was diagnosed as lung cancer, while the control group was Tuberculosis, pneumonia patients. Two groups of patients NSE and CYFRA21-1 joint detection. Results The positive rates of NSE in the observation group and the control group were 37.14% and 35.48%, respectively. The positive rates of CYFRA21-1 alone were 50.00% and 48.39%, respectively. There was no significant difference between the two groups in the positive rate of NSE > 0.05). The positive rates of combined detection in the observation group and the control group were 84.29% and 50.00%, respectively, with significant difference between the two groups (P <0.05). Conclusions Combined detection of serum tumor markers NSE and CYFRA21-1 can greatly improve the diagnostic positive rate of lung cancer and can guide the follow-up treatment.